Among the eight genes described above as having evidence of therapeutic impact in the clinical practice guidance for NGS for cancer diagnosis and treatment,21 the genes most frequently altered were IDH1 (5.8%), ERBB2 (4.2%), RNF43 (3.9%), and FGFR2 (3.2%) in Asian patients with BTC. This evidence concerns the gene ERBB2 and cancer.